HTG Molecular Diagnostics, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-12-02: Form 8-K; Period of report 2015-12-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2015-11-24: Form 8-K; Period of report 2015-11-23; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2015-11-12: Form 8-K; Period of report 2015-11-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-10-27: Form 8-K; Period of report 2015-10-27; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-12-02 | 8-K | 2015-12-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 1, 2015, the Board of Directors (the “Board”) of HTG Molecular Diagnostics, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board (the “Nominating Committee”), appointed James T. LaFrance to serve as a Class I director of the Company with a term expiring at the Company’s annual meeting of stockholders to be held in 2016. | d33764d8k.htm |
| 2015-11-24 | 8-K | 2015-11-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 23, 2015, Donald W. Grimm notified us of his resignation from our Board of Directors (the “Board”) for health reasons, effective immediately. | d89116d8k.htm |
| 2015-11-12 | 8-K | 2015-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2015, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2015. | d46014d8k.htm |
| 2015-10-27 | 8-K | 2015-10-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 27, 2015, Simeon J. George, M.D. notified HTG Molecular Diagnostics, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), as Chairman of the Compensation Committee of the Board (the “Compensation Committee”) and as a member of the Nominating and Governance Committee of the Board (the “Nominating Committee”), effective immediately. | d45122d8k.htm |
| 2015-09-23 | 8-K | 2015-09-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Our principal executive officer, principal financial officer and our other named executive officers (which we refer to herein collectively as “executive officers”) are eligible to receive annual performance-based bonuses pursuant to their employment agreements with us. | d60829d8k.htm |
| 2015-08-11 | 8-K | 2015-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2015, HTG Molecular Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2015. | d23433d8k.htm |
| 2015-07-21 | 8-K | 2015-07-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 16, 2015, Simeon George notified us of his decision to resign from our board of directors (the “Board”) upon the appointment or election of an individual to serve as Dr. George’s successor on the Board. | d140565d8k.htm |
| 2015-06-01 | 8-K | 2015-06-01 | 2.02 Results of Operations and Financial Condition | 2.02 On June 1, 2015, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2015. | d937558d8k.htm |
| 2015-05-12 | 8-K | 2015-05-11 | 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.02 In connection with the closing of the initial public offering of shares of the common stock of HTG Molecular Diagnostics, Inc. (the “Company”), which occurred on May 11, 2015 (the “IPO”), the Company issued 710,060 shares of its Series D preferred stock upon the exercise of outstanding warrants. 5.03 On May 11, 2015, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the IPO. | d924584d8k.htm |